Login to Your Account

Other News To Note

Tuesday, May 7, 2013

• Kala Pharmaceuticals Inc., of Waltham, Mass., presented preclinical data suggesting that topical delivery of a small-molecule receptor tyrosine kinase inhibitor (RTKi) formulated using its mucosal-penetrating particle (MPP) technology enhanced drug levels in the retina.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription